Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / March / Beyond Morphology and IHC
Histology Biochemistry and molecular biology Molecular Pathology Technology and innovation Clinical care

Beyond Morphology and IHC

Can molecular profiling and AI help uncover tumor origin and actionable biomarkers?

By Jessica Allerton 03/16/2026 Discussion 6 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll
  • Top Institutions
  • Top Thought Leaders

Share

Top Institutions in Molecular Pathology and Diagnostic Oncology

Leading institutions utilize advanced molecular diagnostics including next-generation sequencing, gene expression profiling, and integrated bioinformatics approaches combined with traditional pathology expertise to enhance tumor classification accuracy, especially in challenging cases like CUP and poorly differentiated tumors.

  • #1

    Memorial Sloan Kettering Cancer Center

    New York, NY

    MSKCC is a global leader in cancer diagnostics and research, pioneering molecular profiling techniques for CUP and ambiguous tumors, with extensive clinical trials and integrated pathology-molecular programs.

    Key Differentiators

    • Molecular Pathology
    • Oncology
    • Cancer Genomics
  • #2

    Dana-Farber Cancer Institute

    Boston, MA

    Dana-Farber integrates cutting-edge molecular diagnostics with clinical oncology, focusing on biomarker discovery and personalized medicine approaches for diagnostically challenging cancers.

    Key Differentiators

    • Cancer Genomics
    • Molecular Diagnostics
    • Hematology-Oncology
  • #3

    Johns Hopkins Hospital

    Baltimore, MD

    Johns Hopkins has a strong tradition in pathology innovation and molecular diagnostics, with specialized programs addressing diagnostic ambiguity in oncology through integrated molecular and histopathologic approaches.

    Key Differentiators

    • Pathology
    • Molecular Diagnostics
    • Oncology
  • #4

    Mayo Clinic

    Rochester, MN

    Mayo Clinic combines multidisciplinary expertise and advanced molecular testing platforms to improve diagnostic accuracy in ambiguous tumors and CUP, emphasizing clinical applicability and patient outcomes.

    Key Differentiators

    • Molecular Pathology
    • Oncology
    • Diagnostic Medicine
  • #5

    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    UCSF is recognized for its innovative research in molecular oncology and personalized diagnostics, developing novel molecular assays to resolve challenging tumor classifications including CUP.

    Key Differentiators

    • Molecular Oncology
    • Pathology
    • Cancer Genomics

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Jessica Allerton

Deputy Editor, The Pathologist

More Articles by Jessica Allerton

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Redefining Diagnostic Reference Standards
Molecular Pathology
Redefining Diagnostic Reference Standards

January 3, 2022

1 min read

Find out what Horizon Discovery’s diagnostic reference standards can do for your workflow

Non-invasive Prostate Cancer Screening
Molecular Pathology
Non-invasive Prostate Cancer Screening

November 5, 2014

1 min read

Can SERS accurately detect the early stages of the most common male cancer?

Sequencing Access for All
Molecular Pathology
Sequencing Access for All

January 24, 2022

1 min read

An affordable genome sequencing pipeline for low- and middle-income countries

Improving Risk Stratification
Molecular Pathology
Improving Risk Stratification

February 3, 2022

1 min read

Two genes have been identified that may be linked to prostate cancer outcomes

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.